Marian J.P.L. Stevens-Kroef

Dr. Marian J.P.L. Stevens-Kroef

Radboud UMC, Nijmegen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016
Verified
Book Chapter
Closed access
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
ASAnnet Simons
Annet Simons
KRKatrina Rack
Katrina Rack
RHRosalind J. Hastings
Rosalind J. Hastings

18 December 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
RKRowan Kuiper
Rowan Kuiper
SZSonja Zweegman
Sonja Zweegman
MDMark van Duin
Mark van Duin
MVMartin H. van Vliet
Martin H. van Vliet
EBErik H. van Beers
Erik H. van Beers
PSPieter Sonneveld
Pieter Sonneveld
The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk ratio is reduced because of comorbidities and subsequent side effects. We hypothesized that adding gene-expression data to R-ISS would generate a stronger marker. This was tested by combining R-ISS with the SKY92 classifier (SKY-RISS). The HOVON-87/NMSG-18 trial (EudraCT: 2007-004007-34) compared melphalan-prednisone-thalidomide followed by thalidomide maintenance (MPT-T) with melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R). From this trial, 168 patients with available R-ISS status and gene-expression profiles were analyzed. R-ISS stages I, II, and III were assigned to 8%, 75%, and 7% of patients, respectively (3-year overall survival [OS] rates: 80%, 65%, 33%, P = 8 × 10−3). Using the SKY92 classifier, 13% of patients were high risk (HR) (3-year OS rates: standard risk [SR], 70%; HR, 28%; P < .001). Combining SKY92 with R-ISS resulted in 3 risk groups: SKY-RISS I (SKY-SR + R-ISS-I; 15%), SKY-RISS III (SKY-HR + R-ISS-II/III; 11%), and SKY-RISS II (all other patients; 74%). The 3-year OS rates for SKY-RISS I, II, and III are 88%, 66%, and 26%, respectively (P = 6 × 10−7). The SKY-RISS model was validated in older patients from the CoMMpass dataset. Moreover, SKY-RISS demonstrated predictive potential: HR patients appeared to benefit from MPR-R over MPT-T (median OS, 55 and 14 months, respectively). Combined, SKY92 and R-ISS classify patients more accurately. Additionally, benefit was observed for MPR-R over MPT-T in SKY92-RISS HR patients only.

1 January 2014 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
EBEva van Den Berg
Eva van Den Berg
DWDaniel Olde Weghuis
Daniel Olde Weghuis
AKAd Geurts van Kessel
Ad Geurts van Kessel
RPRolph Pfundt
Rolph Pfundt
ASAnnet Simons
Annet Simons
Characteristic genomic abnormalities in patients with B cell chronic lymphocytic leukemia (CLL) have been shown to provide important prognostic information. Fluorescence in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA), currently used in clinical diagnostics of CLL, are targeted tests aimed at specific genomic loci. Microarray-based genomic profiling is a new high-resolution tool that enables genome-wide analyses. The aim of this study was to compare two recently launched genomic microarray platforms, i.e., the CytoScan HD Array (Affymetrix) and the HumanOmniExpress Array (Illumina), with FISH and MLPA to ascertain whether these latter tests can be replaced by either one of the microarray platforms in a clinical diagnostic setting. Microarray-based genomic profiling and FISH were performed in all 28 CLL patients. For an unbiased comparison of the performance of both microarray platforms 9 patients were evaluated on both platforms, resulting in the identification of exactly identical genomic aberrations. To evaluate the detection limit of the microarray platforms we included 7 patients in which the genomic abnormalities were present in a relatively low percentage of the cells (range 5-28%) as previously determined by FISH. We found that both microarray platforms allowed the detection of copy number abnormalities present in as few as 16% of the cells. In addition, we found that microarray-based genomic profiling allowed the identification of genomic abnormalities that could not be detected by FISH and/or MLPA, including a focal TP53 loss and copy neutral losses of heterozygosity of chromosome 17p. From our results we conclude that although the microarray platforms exhibit a somewhat lower limit of detection compared to FISH, they still allow the detection of copy number abnormalities present in as few as 16% of the cells. By applying similar interpretation criteria, the results obtained from both platforms were comparable. In addition, we conclude that both microarray platforms allow the identification of additional potential prognostic relevant abnormalities such as focal TP53 deletions and copy neutral losses of heterozygosity of chromosome 17p, which would have remained undetected by FISH or MLPA. The prognostic relevance of these novel genomic alterations requires further evaluation in prospective clinical trials.

25 February 2017 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
DWDaniel Olde Weghuis
Daniel Olde Weghuis
NENajat ElIdrissi‐Zaynoun
Najat ElIdrissi‐Zaynoun
BRBert van der Reijden
Bert van der Reijden
ECEline M. P. Cremers
Eline M. P. Cremers
JJJoop H. Jansen
Joop H. Jansen

6 December 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
FBFrédéric Baron
Frédéric Baron
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
MKMichal Kicinski
Michal Kicinski
GMGiovanna Meloni
Giovanna Meloni
PMPetra Muus
Petra Muus
SSStefan Suciu
Stefan Suciu
Monosomal karyotype (MK) confers a poor prognosis in patients with acute myeloid leukemia (AML). Here, we determined the impact of the type of remission-induction chemotherapy and the impact of having a donor in younger AML patients with a MK included in two phase III trials. In the first trial, patients were randomized to receive either daunorubicin (DNR), mitoxantrone (MTX), or idarubicin (IDA) in addition to standard-dose cytarabine (SDAC) and etoposide for induction chemotherapy. In the second trial, patients were randomized between either SDAC or high dose cytarabine (HiDAC) induction, both with DNR and etoposide. In both trials, patients who achieved a complete remission with (CR) or without (CRi) complete hematological recovery received an allogeneic hematopoietic stem cell transplantation (allo-HSCT) if they had a donor or an autologous HSCT (auto-HSCT) otherwise. In comparison to patients with intermediate risk cytogenetics without MK (n=1584) and with adverse cytogenetics without MK (n=218), MK+ patients (n=188) were more likely not to achieve a CR/CRi (odds ratio=2.85, 95% confidence interval, CI: 2.10-3.88) and had shorter overall survival (OS) (hazard ratio, HR=2.44, 95% CI: 2.08-2.88) and OS from CR/CRi (HR=2.73, 95% CI: 2.17-3.45). There was no impact of the type of anthracycline or of SDAC vs HiDAC on outcomes in MK+ patients. Among MK+ patients who achieved a CR/CRi, HLA-identical related donor availability was associated with longer survival from CR/CRi (HR=0.59, 95% CI: 0.37-0.95). In summary, these data suggest no benefit of HiDAC in MK+ patients but better OS associated with allo-HSCT.

11 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SRSafaa Ramadan
Safaa Ramadan
SSStefan Suciu
Stefan Suciu
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
RWRoelof Willemze
Roelof Willemze
SASergio Amadori
Sergio Amadori
FBFrédéric Baron
Frédéric Baron
We report the outcomes of secondary acute myeloid leukemia (s-AML) patients included in one of 13 European Organisation for Research and Treatment of Cancer (EORTC) collaborative AML trials using intensive remission-induction chemotherapy. Among 8858 patients treated between May 1986 and January 2008, 960 were identified as having s-AML, either after MDS (cohort A; n = 508), occurring after primary solid tumors or hematologic malignancies other than MDS (cohort B; n = 361), or after non-malignant conditions or with a history of toxic exposure (cohort C; n = 91). Median age was 64 years, 60 years and 61 years in cohort A, B and C, respectively. Among patients ≤60 years and classified in the cohorts A or B (n = 367), the 5-year overall survival (OS) rate was 28%. There was a systematic improvement in the 5-year OS rate over three time periods (p < 0.001): 7.7% (95% CI: 1.3–21.7%) for patients treated before 1990 (period 1: n = 26), 23.3% (95% CI: 17.1–30.0%) for those treated between 1990 and 2000 (period 2: n = 188) and 36.5% (95% CI: 28.7–44.3%) for those treated in 2000 or later (period 3: n = 153). In multivariate analysis, male gender (HR = 1.39; p = 0.01), WBC ≥ 25 × 109/L (HR = 2.00; p < 0.0001), age 46-60 years (HR = 1.65; p < 0.001) and poor-risk cytogenetics (HR = 2.17; p < 0.0001) were independently associated with shorter OS, while being treated during period 2 (HR = 0.50, p = 0.003) or period 3 (HR = 0.43; p = 0.0008). Having received high-dose cytarabine (HD-AraC) (n = 48) in the induction chemotherapy (HR = 0.54, p = 0.012) was associated with a longer OS. In contrast, among patients >60 years of age (n = 502), the OS was dismal, and there was no improvement over time.